Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- The Lancet Announces Retraction of JIKEI Paper on Diovan Trial, Says There’s “Sufficient Doubt”
September 9, 2013
- Tokushukai Group to Cancel Use of Diovan Products at Its 66 Hospitals
August 28, 2013
- Go-Between Faculty Member for Ex-Employee and Osaka City University Received 4 Million Yen in Grants from Novartis
August 26, 2013
- Osaka City University Slams Lead Investigators of Diovan Trials; They “Knew of His Novartis Affiliation”
August 26, 2013
- JSMO Announces Guidance on Prevention and Treatment of Tumor Lysis Syndrome; Rasburicase Recommended for High-risk Patients
August 22, 2013
- Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
- JASDI Conducting Survey on Inconsistencies in Package Inserts of Similar Drugs; Will Come Up with Improvement Proposal by Year-End
August 19, 2013
- JSGM Initiates Plan to Unify Brand Names of Generic Fixed-dose Combination Drugs to Prevent Medication Errors
August 19, 2013
- St. Marianna University School of Medicine Hospital Ends Use of Diovan for Patients
August 16, 2013
- British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
- Japan Hypertension Society Sets Up Ethics Committee amid Diovan Fuss
August 8, 2013
- Japan Hypertension Society Deletes Citations of JIKEI Study from Treatment Guidelines
August 8, 2013
- NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
August 7, 2013
- Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
August 6, 2013
- The Lancet Has Not Received Notification from Jikei University on Investigation Findings: Spokesperson
August 1, 2013
- Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
July 31, 2013
- Role of Companies in Clinical Research Discussed at JAPhMed Annual Meeting
July 24, 2013
- University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
- Univ. Fails to Question Ex-Novartis Employee over KYOTO Study, Says Internal Probe “Has Limitations”
July 16, 2013
- “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…